Press Releases
 
Cytomegalovirus Retinitis Market Trends, Size, Growth and Demand, 2023

United States, 8 December 2017 -- One of the major trends noticed in the cytomegalovirus retinitis market is usage of off-label drugs for the treatment of cytomegalovirus retinitis.

Innovation of products focusing on better efficacy, growing demographics and growing economies in the developing countries, such as China and India, are some of the opportunities for global cytomegalovirus retinitis market.

Cytomegalovirus retinitis is eye disease caused due to retina inflammation of eye. The causative agent of the disease is cytomegalovirus, a herpes virus that affects the photosensitive cells of retina. After affecting the retina, the disease spreads from one eye to another eye, which can lead to blindness, if left untreated. Photophobia, blurred vision, seeing floaters and blind spots are the symptoms of cytomegalovirus retinitis. Cytomegalovirus retinitis usually affects people with weak immune system, including HIV affected patients. Various forms of cytomegalovirus retinitis medication are solutions, capsules, tablets and implants.

To know more about Cytomegalovirus Retinitis Market: https://www.psmarketresearch.com/market-analysis/cytomegalovirus-retinitis-market

Cytomegalovirus retinitis is an emergency situation because if a black spot in the visual field appears once, the disease cannot be cured due to its permanent in nature. If posterior pole is involved, it leads to approximately one half of incident visual acuity loss. Ophthalmology is the branch of medical science that deals with the study and management of physiology, anatomy and the diseases related to the human eye. The vision loss and incidence of eye disorders are becoming a major public health issues which include various eye diseases such as glaucoma, age-related macular degeneration, cataract, diabetic macular edema, retinal detachment, ocular hypertension, bulging eyes, refractive errors and uveitis. Active cytomegalovirus retinitis is generally treated by uveitis or ocular immunology specialist. Fomivirsen was the first antisense drug approved by the U.S. Food and Drug Administration (FDA) as an intraocular injection for curing cytomegalovirus retinitis. As the virus creates a worse effect to vision, it is generally treated by a vitreoretinal surgeon with the help of antivirals, such as ganciclovir or foscarnet, which can be taken orally or directly into the eye.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/cytomegalovirus-retinitis-market/report-sample

Some of the major competitors of global cytomegalovirus retinitis market are, Shire Plc, F. Hoffmann-La Roche AG, Hospira Inc., Chimerix Inc., Gilead Sciences Inc., pSivida, Auritec Pharmaceuticals Inc., Sanofi S.A., and Isis Pharmaceuticals Inc.

# # #


Submitted by Jacob, P&S Market Research on Friday, 8 December 2017 at 6:18 AM
Category: Health Care & Medical
 
Related News

Dental Caries and Endodontic Market: Segmental Highlights and Table of Content (2017-2027)
Thursday, 14 Dec 2017

Continuous Peripheral Nerve Block Catheter Market: Segment Snapshot and TOC (2016 - 2026)
Thursday, 14 Dec 2017

Asia-Pacific Hospital Beds Market Growth Factors, Consumption, Market Current Scenario, 2023
Thursday, 14 Dec 2017

Law of Attraction - The Missing Key Event, to be launched by the Hypnosis Of Portland Center
Thursday, 14 Dec 2017

Companion Animal Drug Market: Segmental Highlights and Table of Content (2015-2025)
Wednesday, 13 Dec 2017

Related Events

Pelvic Anatomy and Gynecologic Surgery Symposium (PAGS)
Thursday, 14 Dec 2017

25th Annual World Congress
Thursday, 14 Dec 2017

Third Emirates Surgical Pathology Conference (ESPC 2017)
Thursday, 14 Dec 2017

Echo on Marco Island: Case-Based Approach
Monday, 18 Dec 2017

Winter Imaging In Beaver Creek
Tuesday, 2 Jan 2018

Latest News

Lamborghini tuning and Luxury wheels make your car look more elegant
Thursday, 14 Dec 2017

Dental Caries and Endodontic Market: Segmental Highlights and Table of Content (2017-2027)
Thursday, 14 Dec 2017

ThemeVPS Is Offering Reliable and Affordable VPS Solutions
Thursday, 14 Dec 2017

Dolphin Data Lab Releases Data Recovery Tool to Recover Data from Undetected Hard Drives
Thursday, 14 Dec 2017

Streamline your stocktake with 6 simple steps
Thursday, 14 Dec 2017

 
Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2017
Today is Thursday, 14 December 2017

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Business
Consumer Technology
Economy
Education
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
Legal/Law
News & Media
Religion
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!


Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.


  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.


    Resources
  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • SMi's 12th annual Cold Chain Distribution Conference and Exhibition
  • Pelvic Anatomy and Gynecologic Surgery Symposium (PAGS)
  • 25th Annual World Congress
  • Third Emirates Surgical Pathology Conference (ESPC 2017)
  • Leadership Course for Directors

  • Latest Jobs
    Sorry, there are currently no entries posted here.